Proton Pump Inhibitors (PPIs) are widely prescribed for the management of Gastroesophageal Reflux Disease (GERD), a common condition characterized by acid reflux and heartburn. This assessment evaluates the efficacy of PPIs in alleviating symptoms, promoting esophageal healing, and improving the quality of life in GERD patients. Clinical studies and meta-analyses demonstrate that PPIs are highly effective in reducing gastric acid secretion, providing rapid symptom relief, and achieving mucosal healing in erosive esophagitis. However, their long-term use raises concerns about potential side effects, such as nutrient deficiencies, increased risk of infections, and rebound acid hypersecretion[1]. While PPIs remain the cornerstone of GERD treatment, their efficacy must be balanced with individualized patient considerations, including the severity of symptoms, underlying conditions, and risk of adverse effects. This review highlights the need for judicious use of PPIs, emphasizing short-term therapy for acute management and exploring alternative strategies for long-term maintenance. Overall, PPIs are highly effective in managing GERD, but their use should be tailored to optimize patient outcomes while minimizing risks.